12:28 PM EDT, 08/27/2025 (MT Newswires) -- Biogen's (BIIB) zuranolone oral treatment for moderate or severe postnatal depression was approved by the United Kingdom's Medicines and Healthcare products Regulatory Agency, the medical regulator said Wednesday.

Zuranolone will be available as a capsule and can be taken orally, at night with a fat-containing meal for 14 days, MHRA said.

Side effects from the product may include memory impairment, confusion, drowsiness, dizziness, sedation, tremor, diarrhea, and fatigue, the regulator added.

Price: 136.67, Change: -0.05, Percent Change: -0.04